Anders Sundan

Anders Sundan is affiliated with the Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine. His work focuses on multiple myeloma, bone morphogenetic proteins (BMP), and cancer biology. He has contributed to understanding BMP signaling's role in myeloma cell survival and therapeutic targets like c-MYC and HGF/c-Met pathways. His research spans cell signaling, bone metabolism, and immunotherapy strategies for hematologic malignancies.

• Education/Positions: PhD, active researcher at NTNU, supervising doctoral students in myeloma and bone disease research.
• Research Interests: Myeloma pathogenesis, BMP/TGF-β signaling, oncogene addiction (e.g., c-MYC), and drug development for bone-related complications.

Publications highlight mechanisms of tumor microenvironment interactions, apoptosis induction via natural compounds, and genetic mutations in blood disorders. His work bridges basic science and clinical applications, aiming to improve myeloma treatment strategies.

• Advising: Supervised doctoral students including Oddrun Elise Olsen and Toril Holien, focusing on BMP receptor roles and c-MYC dependency in myeloma.
• Labs/Teams: Collaborates with CEMIR and the Department of Cancer Research and Molecular Medicine at NTNU.